Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 29, 2025
Daily News
October 29, 2025
- LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
- J-TEC, AlliedCel Ink Service Contract for T-Cell Therapy Production
October 29, 2025
- Japan Gives Orphan Tags for Kyowa Kirin’s Gene Therapy, Cuorips’ Cell Sheet
October 29, 2025
- Japan PM Warns of Overreliance on China for Pharmaceutical Ingredients
October 29, 2025
- Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…